MedElevator
Войти в исследования Current opinion in urology · 2026
Impact of a multidisciplinary approach on outcomes in urothelial carcinoma.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Neuenschwander Anne, Uleri Alessandro, Grobet-Jeandin Elisabeth, Contieri Roberto, Pradere Benjamin
Аннотация
PURPOSE OF REVIEW: Urothelial carcinoma demonstrates high prevalence and is characterized by significant clinical heterogeneity. As treatment options expand, therapeutic decisions become more complex, giving multidisciplinary teams (MDT) a crucial role. This review summarizes current evidence on the impact of a multidisciplinary approach on outcomes in urothelial carcinoma.
RECENT FINDINGS: Most urothelial carcinoma data derive from bladder cancer studies, where MDT have a substantial impact on diagnostic accuracy, improved staging quality and treatment recommendations. MDT often implement treatment changes such as the addition of intravesical or systemic therapies and improve adherence to clinical guidelines. This is associated with improved patient outcomes, although data on the effect on patient survival remains limited.
SUMMARY: The therapeutic landscape for urothelial carcinoma is rapidly evolving with the implementation of new therapeutic options, making multidisciplinary collaboration essential for personalized treatment strategy. MDT ensure optimal diagnostical pathways, establishment of comprehensive treatment strategies, and thus potential survival benefits.
RECENT FINDINGS: Most urothelial carcinoma data derive from bladder cancer studies, where MDT have a substantial impact on diagnostic accuracy, improved staging quality and treatment recommendations. MDT often implement treatment changes such as the addition of intravesical or systemic therapies and improve adherence to clinical guidelines. This is associated with improved patient outcomes, although data on the effect on patient survival remains limited.
SUMMARY: The therapeutic landscape for urothelial carcinoma is rapidly evolving with the implementation of new therapeutic options, making multidisciplinary collaboration essential for personalized treatment strategy. MDT ensure optimal diagnostical pathways, establishment of comprehensive treatment strategies, and thus potential survival benefits.